

**genedrive plc**  
**("genedrive" or the "Company")**  
**Genedrive® MT-RNR1 ID Kit implemented at Dublin's Rotunda Hospital**

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that the Genedrive® MT-RNR1 ID Kit has been implemented at Dublin's Rotunda Hospital Neonatal Intensive Care Unit ("NICU"). The Rotunda Hospital implementation is in addition to the 14 hospitals in the UK that are currently utilising the Genedrive® MT-RNR1 ID Kit under the PALOH-UK programme.

Funded initially by the Rotunda Foundation under the "Early Identification of Susceptibility to Gentamicin Induced Hearing Loss" programme, Rotunda Hospital admits approximately 1,400 babies each year into its NICU.

Further details are available at:

<https://www.pressreader.com/ireland/irish-independent/20251101/281616721613956>

**Dr Gino Miele, CEO of genedrive plc, said:** "Implementation at Rotunda Hospital is further validation of the product-market fit of our MT-RNR1 ID kit. Funded through a charitable foundation and led by Professor Brian Cleary, who has personal experience of hearing loss requiring a cochlear implant, we are excited to see the test being implemented internationally, in addition to those in PALOH-UK and the NHS England framework."

**Prof. Brian Cleary, Pharmacy Executive Manager, Rotunda Hospital, Dublin, said:** "We are very excited to have access to point-of-care pharmacogenetic testing technology which enables us to identify babies at risk of significant hearing loss quickly and effectively. The EISTIGI project, supported by the Charlotte Stoker Fund, presents an exciting opportunity to assess the feasibility of point of care pharmacogenomics testing in this setting."

**Prof. Breda Hayes, Consultant Neonatologist, Rotunda Hospital, Dublin, said:** "We are really happy with how the implementation is progressing. Bedside testing is a fantastic addition to the care that we provide, offering reassurance that we can reduce the risk of gentamicin-induced hearing loss in our most vulnerable patients."

For further details please contact:

**genedrive plc** +44 (0)161 989 0245

Gino Miele: CEO / Russ Shaw: CFO

**Peel Hunt LLP (Nominated Adviser and Broker)** +44 (0)20 7418 8900

James Steel

**Walbrook PR Ltd (Media & Investor Relations)** +44 (0)20 7933 8780 or [genedrive@walbrookpr.com](mailto:genedrive@walbrookpr.com)

Anna Dunphy

+44 (0)7876 741 001

**About genedrive plc ( <http://www.genedrive.com> )**

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicine's ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a world's-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCDDBBBDGDGUX